Expression And Significance Of Glypican-3, ?-catenin And GSK-3? In Prostate Cancer

Objective: Prostate cancer(Prostate cancer,PCa)is one of common malignant tumors in older men.The incidence of Prostate cancer in American and European countries ranks first in male tumors,its mortality rate is only second to Lung cancer.Although the incidence of Prostate cancer in China is lower than Western countries,but as the accelerating aging of the social population,the changing of diet structure and the popularizing of Prostate cancer screening,its incidence rate and cancer detection rate increasing year by year,and in most place of China,there are more advanced Prostate cancer in the newly diagnosed patients than European and American countries,which has a bad impact on the treatment effect and prognosis of Prostate cancer patients.Therefore,it is quite significant to further explore the pathogenesis of Prostate cancer and the new ways of early diagnosis and treatment for Prostate cancer patients.Study found that Phosphatidylinositol proteoglycan-3(Glypican-3,GPC-3)showed high expression in Prostate cancer tissues,and closely related to the classical Wnt signaling pathway,which is expected to become a new tumor markers of Prostate cancer.This research by means of detecting the expression of GPC-3,?-catenin and GSK-3? in Prostate cancer tissues and Benign prostatic hyperplasia tissues,to analyze the significance of GPC-3,?-catenin and GSK-3? protein in Prostate cancer and the possible relationships with the classical Wnt signaling pathway,to explore new tumor markers for Prostate cancer;by means of detecting serum GPC-3 level in Prostate cancer patients,to investigate the clinical value of GPC-3 joint PSA test in diagnosis of Prostate cancer patients,to explore new methods to improve the accuracy of Prostate cancer clinical diagnosis.Methods:1 The immunohistochemical method S-P was used to detect the protein of GPC-3,?-catenin and GSK-3? in 40 cases of Prostate cancer tissues and 30 cases of Benign prostate hyperplasia tissues,the expression and significance of GPC-3,?-catenin and GSK-3? in Prostate cancer and Benign prostatic hyperplasia were retrospectively analyzed.2 The ELISA method was used to detect serum GPC-3,and radioimmunoassay(RIA)method to detect serum tPSA and fPSA,then analysed the serum GPC-3,tPSA and fPSA detection results in 35 cases of Prostate cancer,100 cases of Benign prostatic hyperplasia and 30 cases of healthy people,and analysed the diagnostic value of GPC-3 combined with tPSA.3 The statistical software SPSS21.0 was used to analyse experimental data,the difference was considered statistically significant at P < 0.05.Results:1 Expression of GPC-3 in Prostate cancer tissues and Benign prostatic hyperplasia tissues: the positive expression rate of GPC-3 was 82.5%(33/40)in Prostate cancer tissues,the positive expression rate of GPC-3 was 13.3%(4/30)in Benign prostatic hyperplasia tissues,and the difference was statistically significant(P < 0.01).2 Expression of ?-catenin in Prostate cancer tissues and Benign prostatic hyperplasia tissues: the positive expression rate of ?-catenin was 90.0%(36/40)in Prostate cancer tissues,the positive expression rate of ?-catenin was 23.3%(7/30)in Benign prostatic hyperplasia tissues,and the difference was statistically significant(P < 0.01).3 Expression of GSK-3? in Prostate cancer tissues and Benign prostatic hyperplasia tissues: the positive expression rate of GSK-3? was 17.5%(7/40)in Prostate cancer tissues,the positive expression rate of GSK-3? was 43.3%(13/30)in Benign prostatic hyperplasia tissues,and the difference was statistically significant(P < 0.05).4 Correlation analysis of GPC-3,?-catenin and GSK-3? : The Spearman rank correlation test showed that GPC-3 and ?-catenin was positively correlated(rs = 0.70,P < 0.01);GSK-3? and ?-catenin was negatively correlated(rs =-0.50,P < 0.01);GPC-3 and GSK-3? did not constitute a linear correlation(rs = 0.29,P = 0.07).The expression of GPC-3 and ?-catenin was associated with Prostate cancer clinical stages and Prostate weight,the greater the clinical stage and Prostate weight,the higher positive expression intensity of GPC-3 and ?-catenin.5 Expression of GPC-3 and tPSA in serum: The serum GPC-3 averaged 137.3±9.6 pg/ml,tPSA averaged 77.2±14.8 ng/ml in Prostate cancer patients;The serum GPC-3 averaged 270.0±16.4 pg/ml,tPSA averaged 8.6±1.0 ng/ml in Benign prostatic hyperplasia patients;The serum GPC-3 averaged 59.0±7.1 pg/ml,tPSA averaged 1.3±0.2 ng/ml in healthy people.6 The specificity and sensitivity of GPC-3 alone detection were 69.4% and 94.3%.The specificity and sensitivity of tPSA alone detection were 90.6% and 47%.The specificity and sensitivity of GPC-3 joint tPSA detection were 91.5% and 87.6%.Conclusions:1 GPC-3 and ?-catenin showed high expression in Prostate cancer tissues,but low expression in Benign prostatic hyperplasia tissues,which indicated that GPC-3 and ?-catenin might play a role on the occurrence and development of Prostate cancer.Thus,GPC-3 and ?-catenin protein can be used for immunodiagnosis of Prostate cancer.2 GPC-3 was positively correlated with ?-catenin,GSK-3? was negatively correlated with ?-catenin,GPC-3 and GSK-3? did not constitute a linear correlation,which indicates that the classical Wnt signaling pathway has been activated in Prostate cancer,GPC-3 may play a role on the occurrence and development of Prostate cancer through the classical Wnt signaling pathway.3 Expression of GPC-3 and ?-catenin was associated with Prostate cancer clinical stage and Prostate weight,the greater the clinical stage and Prostate weight,the higher positive expression intensity of GPC-3 and ?-catenin.Therefore,GPC-3 and ?-catenin has the potential to predict the Prostate cancer prognosis.4 GPC-3 combined with tPSA detection can improve the accuracy of Prostate cancer diagnosis.